PURPOSE: Despite a lack of active angiogenesis, VEGF is expressed in nearly every adult tissue, and recent evidence suggests that VEGF may serve as a survival factor for both vascular and nonvascular tissues. VEGF blockade is a widely used treatment for neovascular diseases such as wet age-related macular degeneration (AMD). Therefore, it was sought in this study to evaluate the expression and role of endogenous VEGF in RPE. METHODS: VEGF and VEGFR2 expression in the murine retina were assessed during development. Bevacizumab was used to neutralize VEGF in ARPE-19 cells, and the effects on cell survival and apical microvill were assessed by TUNEL and SEM, respectively. VEGF was systemically neutralized in vivo by adenoviral-mediated overexpression of soluble VEGFR1 (sFlt). RPE and choriocapillaris were analyzed by transmission electron microscopy (TEM). Changes in gene expression were evaluated by quantitative real-time PCR. RESULTS: VEGF expression was detected in the developing RPE as early as embryonic day (E) 9.5, whereas VEGFR2 expression by RPE began nonuniformly between postnatal (P) day 6.5 and P8.5. VEGF neutralization in vitro led to increased apoptosis and reduced microvilli density and length. Systemic VEGF neutralization led to transient degenerative changes; RPE were vacuolated and separated from photoreceptor outer segments, and choriocapillaris fenestrations were decreased. VEGF levels were elevated in RPE of Ad-sFlt1 mice at day 4 postinfection, and there was increased expression of the neurotrophic factor CD59a at day 14. CONCLUSIONS: These results indicate that VEGF plays a critical role in survival and maintenance of RPE integrity. Potential undesired off-target effects should be considered with chronic use of anti-VEGF agents.
PURPOSE: Despite a lack of active angiogenesis, VEGF is expressed in nearly every adult tissue, and recent evidence suggests that VEGF may serve as a survival factor for both vascular and nonvascular tissues. VEGF blockade is a widely used treatment for neovascular diseases such as wet age-related macular degeneration (AMD). Therefore, it was sought in this study to evaluate the expression and role of endogenous VEGF in RPE. METHODS:VEGF and VEGFR2 expression in the murine retina were assessed during development. Bevacizumab was used to neutralize VEGF in ARPE-19 cells, and the effects on cell survival and apical microvill were assessed by TUNEL and SEM, respectively. VEGF was systemically neutralized in vivo by adenoviral-mediated overexpression of soluble VEGFR1 (sFlt). RPE and choriocapillaris were analyzed by transmission electron microscopy (TEM). Changes in gene expression were evaluated by quantitative real-time PCR. RESULTS:VEGF expression was detected in the developing RPE as early as embryonic day (E) 9.5, whereas VEGFR2 expression by RPE began nonuniformly between postnatal (P) day 6.5 and P8.5. VEGF neutralization in vitro led to increased apoptosis and reduced microvilli density and length. Systemic VEGF neutralization led to transient degenerative changes; RPE were vacuolated and separated from photoreceptor outer segments, and choriocapillaris fenestrations were decreased. VEGF levels were elevated in RPE of Ad-sFlt1mice at day 4 postinfection, and there was increased expression of the neurotrophic factor CD59a at day 14. CONCLUSIONS: These results indicate that VEGF plays a critical role in survival and maintenance of RPE integrity. Potential undesired off-target effects should be considered with chronic use of anti-VEGF agents.
Authors: Michael I Dorrell; Edith Aguilar; Lea Scheppke; Faith H Barnett; Martin Friedlander Journal: Proc Natl Acad Sci U S A Date: 2007-01-08 Impact factor: 11.205
Authors: Sophie J Bakri; J Douglas Cameron; Colin A McCannel; Jose S Pulido; Ronald J Marler Journal: Am J Ophthalmol Date: 2006-07 Impact factor: 5.258
Authors: Alexander G Marneros; Jie Fan; Yoshihito Yokoyama; Hans Peter Gerber; Napoleone Ferrara; Rosalie K Crouch; Bjorn R Olsen Journal: Am J Pathol Date: 2005-11 Impact factor: 4.307
Authors: Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima Journal: Am J Pathol Date: 2007-07 Impact factor: 4.307
Authors: Maria Nawrot; Karen West; Jing Huang; Daniel E Possin; Anthony Bretscher; John W Crabb; John C Saari Journal: Invest Ophthalmol Vis Sci Date: 2004-02 Impact factor: 4.799
Authors: Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore Journal: PLoS One Date: 2008-11-03 Impact factor: 3.240
Authors: Thomas Bertelmann; Stephan Schulze; Reka Bölöni; Walter Sekundo; Sebastian Irle; Thomas Stief; Stefan Mennel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-02-04 Impact factor: 3.117
Authors: Emma C Zanzottera; Thomas Ach; Carrie Huisingh; Jeffrey D Messinger; K Bailey Freund; Christine A Curcio Journal: Retina Date: 2016-12 Impact factor: 4.256
Authors: S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins Journal: Prog Retin Eye Res Date: 2014-12-05 Impact factor: 21.198
Authors: Wen Allen Tseng; Thuzar Thein; Kati Kinnunen; Kameran Lashkari; Meredith S Gregory; Patricia A D'Amore; Bruce R Ksander Journal: Invest Ophthalmol Vis Sci Date: 2013-01-07 Impact factor: 4.799
Authors: Leo A Kim; Dhanesh Amarnani; Gopalan Gnanaguru; Wen Allen Tseng; Demetrios G Vavvas; Patricia A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 2014-07-03 Impact factor: 4.799
Authors: Mandrita Bagchi; Leo A Kim; Jeremie Boucher; Tony E Walshe; C Ronald Kahn; Patricia A D'Amore Journal: FASEB J Date: 2013-05-16 Impact factor: 5.191